News | February 14, 2025
IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Branded formulation business continues to perform well across domestic and export markets
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The product will be marketed by Dr. Reddy's
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
The transaction involves the acquisition of 100% shareholding of Bharat Serums and Vaccines (BSV) by Mankind Pharma
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Subscribe To Our Newsletter & Stay Updated
